AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
2articles mentioning drugs
2drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: capmatinib ×
capmatinib
This drug is selected. Its supporting articles are shown below.
Articles mentioning capmatinib
2 articles · page 1 of 1DenosumabCapmatinibAtezolizumabCarboplatinAtezolezumabPemetrexedPemetexedCampatinibnon-small cell lung cancerNSCLC
…palliative ChT-IO with Atezolezumab + Pemetexed + Carboplatin + Denosumab followed by Maintenance Chemo IO with Pemetrexed + Atezolizumab…